Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Revvity ( (RVTY) ) is now available.
At its April 28, 2026 annual meeting, Revvity shareholders elected ten directors to one-year terms and ratified Deloitte & Touche LLP as the independent public accounting firm for the current fiscal year. Investors also approved, on a non-binding basis, the company’s executive compensation program, signaling broad support for existing pay practices.
Shareholders backed an amendment to the company’s bylaws allowing holders of 25% of outstanding common stock to call a special meeting, enhancing investor rights and governance flexibility. A shareholder proposal on executive stock ownership, however, was rejected, indicating investors were satisfied with current equity ownership policies or wary of additional constraints on management incentives.
The most recent analyst rating on (RVTY) stock is a Hold with a $95.00 price target. To see the full list of analyst forecasts on Revvity stock, see the RVTY Stock Forecast page.
Spark’s Take on RVTY Stock
According to Spark, TipRanks’ AI Analyst, RVTY is a Neutral.
The score is primarily driven by solid financial performance led by strong free-cash-flow generation and improved leverage, tempered by weaker profitability versus prior years. Technicals are constructive longer term but show near-term consolidation. Valuation is the biggest constraint due to the high P/E and low yield, while the latest earnings call supports a moderately positive view with steady EPS/FCF outlook but only modest growth and near-term margin pressure.
To see Spark’s full report on RVTY stock, click here.
More about Revvity
Revvity is a life sciences and diagnostics company that provides technologies, assays, reagents, and analytical instruments to pharmaceutical, biotech, and clinical customers. The company focuses on advancing research, drug development, and diagnostic testing in global healthcare and scientific markets.
Average Trading Volume: 1,187,749
Technical Sentiment Signal: Sell
Current Market Cap: $9.68B
For an in-depth examination of RVTY stock, go to TipRanks’ Overview page.